The 30-second summary
- GLP-1s improve insulin sensitivity through direct receptor effects and indirectly through weight loss.
- Markers of insulin resistance (fasting insulin, HOMA-IR, HbA1c if elevated) often improve within 4–12 weeks, sometimes before substantial weight loss.
- For women with PCOS, prediabetes, or a family history of type-2 diabetes, this is one of the most clinically meaningful effects of the drug, and worth tracking specifically.
Why this matters
Insulin resistance, the state in which your cells respond less effectively to insulin, is the upstream driver of much of metabolic disease. It predicts type-2 diabetes, cardiovascular disease, fatty liver, PCOS-related infertility, and a range of other conditions decades before they manifest.
For many women starting a GLP-1, insulin resistance is the underlying problem the drug is treating. Weight loss is the visible outcome; metabolic recalibration is the deeper one.
The good news: insulin resistance is one of the fastest-moving metabolic markers on a GLP-1. It often improves before the weight does.
How GLP-1s improve insulin sensitivity
Three mechanisms, all real:
- Direct GLP-1 receptor effects on the pancreas. GLP-1 stimulates insulin secretion only when blood glucose is elevated, and suppresses glucagon. This is glucose-dependent, the drug does not cause hypoglycaemia on its own.
- Reduced visceral fat. Visceral fat (deep abdominal fat) is metabolically active and drives insulin resistance. GLP-1 weight loss preferentially reduces visceral fat, substudies of the STEP and SURMOUNT trials confirmed this with DXA imaging.
- Reduced hepatic fat. Fatty liver is closely linked to insulin resistance. GLP-1s reduce liver fat content in a way that goes beyond what would be expected from weight loss alone. (Newsome PN et al., NEJM 2021, on semaglutide in NASH.)
The result is a measurable improvement in nearly every marker of metabolic health within weeks of starting.
The markers worth tracking
A baseline-and-follow-up panel that captures the metabolic story:
Fasting glucose
The most common test. Normal is below 100 mg/dL (5.6 mmol/L). Prediabetes is 100–125 mg/dL (5.6–6.9 mmol/L). Diabetes is 126+ (7.0+).
On a GLP-1, fasting glucose typically drops modestly even in women without diabetes, usually a few points, often back into the normal range from prediabetes.
HbA1c (glycated haemoglobin)
A three-month average of blood glucose. Normal is below 5.7%. Prediabetes is 5.7–6.4%. Diabetes is 6.5%+.
For women with prediabetes or early type-2 diabetes, the HbA1c improvement on a GLP-1 is often the most clinically important number on the panel.
Fasting insulin
Less commonly ordered, but more sensitive than glucose. A fasting insulin level below 10 µIU/mL is the typical target; many women with insulin resistance run 15–25 or higher even with normal fasting glucose.
This is the marker that often changes earliest on a GLP-1.
HOMA-IR
A calculation combining fasting glucose and fasting insulin. Below 2 is good; 2–3 is borderline; above 3 indicates significant insulin resistance.
Triglycerides and HDL
Both move with insulin resistance. Triglycerides drop, HDL often rises modestly. These are part of the standard lipid panel.
What the timeline looks like
A common pattern across women starting a GLP-1:
- Weeks 2–4: Fasting glucose drops modestly. Fasting insulin can drop significantly. Most women do not feel a metabolic difference yet.
- Weeks 4–12: HbA1c begins to improve (it lags because it averages over time). Triglycerides drop. Visible weight loss is well underway.
- Months 3–6: All markers are typically meaningfully better than baseline. Liver enzymes (ALT, AST) improve in women with elevated baseline values.
- Months 6–12: The metabolic profile of many women is now substantially different from what it was. Some women cross out of prediabetes; some cross out of diabetes.
This is not just a weight-loss benefit. It is a separate, parallel benefit of the drug.
Why this matters for prevention
For a woman in her 40s with a family history of type-2 diabetes, a baseline fasting glucose of 105 mg/dL, and 15 kg of excess weight, the question is not just "how much weight can I lose?" It is also "what is the metabolic trajectory I am on if I do nothing, versus the trajectory I am on with the drug?"
The DPP study (Diabetes Prevention Program) showed that meaningful weight loss reduces diabetes incidence by about 58% over three years in people with prediabetes. (DPP Research Group, NEJM 2002.) GLP-1s reliably produce that magnitude of weight loss, plus the additional direct metabolic effects.
The case for a GLP-1 in this group is not "I want to look different." It is "I want a different decade."
What to ask about at your next appointment
A short list:
- Can we add fasting insulin to my next blood draw? Most standard panels skip it. It is a useful baseline.
- What was my HbA1c before I started? And what is it now, after 3–6 months?
- Has my fasting glucose moved? If you were in prediabetes range, where are you now?
- What does my liver function look like? ALT and AST, if you had elevated baseline values.
- What about my lipid panel? Triglycerides, HDL, total cholesterol.
The metabolic story is the story the scale does not tell.
What this is not
This is not a recommendation to start a GLP-1 for insulin resistance alone. The drug's approved uses are type-2 diabetes and obesity-class indications. Off-label use for insulin resistance without overweight or obesity is uncommon and not well-studied.
What this is: a framing. If you are taking the drug for weight, the metabolic benefits are coming along with the ride, and they are often more clinically important than the weight number itself.
What Steady does with this
If you record your blood test results in Steady, the progress view tracks them alongside weight and dose. The pattern, fasting insulin falling first, weight following, HbA1c last, is visible across a year of data. This is the chart most women have never seen of their own bodies.
Sources
- Newsome PN et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. NEJM 2021. NEJM
- DPP Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. NEJM 2002. NEJM
- Drucker DJ. Mechanisms of Action and Therapeutic Application of GLP-1. Cell Metab 2018. Cell Metab
- Jastreboff AM et al. SURMOUNT-1. NEJM 2022. NEJM
Medical disclaimer: Interpretation of metabolic test results belongs with your physician, who has your full context. See our full medical disclaimer.